In short
Across randomised trials at 240 to 600 mg of root extract, ashwagandha's side effects are mild, transient and statistically comparable to placebo. Two signals live outside the trials and deserve naming: rare, idiosyncratic liver injury known from case reports, and measurable thyroid hormone activity shown in one trial, which matters to anyone on thyroid medication. Pregnancy, sedatives, autoimmune conditions and liver disease are the other reasons to skip it. The widely shared emotional blunting reports are anecdote with no trial signal so far; we take them seriously enough to say exactly that. Within trial durations of 8 to 12 weeks, effects hold with no tolerance signal; beyond a year, data thins out, and we say that too.
A brand that sells an ingredient owes readers its complete safety page, written at least as sceptically as an outsider would write it. This is that page.
01What the trials show
The controlled evidence is reassuring and consistent: a 2026 systematic review of trials in healthy adults found adverse events mild and transient, mostly digestive upset and drowsiness, at rates comparable to placebo.1 A 12 month observational study found no serious safety signals over a year of use.2 Trial doses run 240 to 600 mg of root extract daily; the 300 mg of KSM-66 in the evening layer sits in the lower middle of that studied range, deliberately.
02Signal one: the liver reports
Outside the trials, medicine keeps case files. The NIH's LiverTox database records ashwagandha as a rare cause of liver injury, typically cholestatic, idiosyncratic, arising two to twelve weeks into use and usually resolving after stopping.3 A documented case series from Iceland and the US DILIN network describes five such cases, all of which resolved.4 Set against millions of users these are rare events, and rare is not zero: new jaundice, dark urine or unexplained itching during use means stop and see a doctor, with no herbal exceptionalism about it.
03Signal two: thyroid activity
The second signal is pharmacological rather than toxic. In a randomised trial in people with subclinical hypothyroidism, eight weeks of ashwagandha at 600 mg significantly lowered TSH and raised thyroid hormones.5 Read positively, that is real biological activity. Read cautiously, it means anyone on levothyroxine or with a thyroid condition should involve their doctor before adding ashwagandha, because a supplement that moves thyroid hormones can move a carefully titrated dose off its mark.
04Who should not take it
The list is short and firm, and it matches the ingredient page: pregnancy and breastfeeding, where traditional use concerns and regulatory assessments both counsel against it; thyroid medication, per the above; sedatives and sleep medication, since effects may add; autoimmune conditions, where immune stimulating botanicals warrant medical advice; and existing liver disease. None of this is unusual for a pharmacologically active botanical, which is precisely the point: it is active, and honest labelling treats it that way.
05The blunting anecdotes
The honest read on the anecdotes
Online, the most discussed ashwagandha effect is emotional blunting, feeling flattened rather than calmed. The trial record contains no such signal: no randomised study has reported anhedonia or emotional flattening as an outcome or adverse event. That does not make the reports false; anecdote is where real rare effects surface first, and it is also where expectation and attribution run loudest. Our honest position: unverified, worth watching, and if you personally feel flattened rather than steadied, stop taking it. Your n of one outranks our citations for your own body.
06Does it stop working
The tolerance question has a clean answer within trial windows and an honest gap beyond them. Across 8 to 12 week trials, effects on stress measures hold or grow through the course, with no attenuation signal of the caffeine kind.6 Beyond roughly a year, controlled data does not exist, and anyone claiming certainty either way is past the evidence. The mechanism differs fundamentally from stimulant tolerance, as tolerance and cycling explains, and the honest sentence is: sustained within studied durations, unknown beyond them.
07The regulatory picture
Ashwagandha's EU status is in motion: Denmark restricted it following a 2020 national risk assessment focused on thyroid and hormonal effects, some member states have followed with restrictions of their own, and the assessment itself has drawn published criticism; discussion at EU level continues as of mid 2026. We state that plainly because readers will encounter it, and because the concerns it raises, thyroid activity and pregnancy, are exactly the ones already on this page. This page reflects the record as of August 2026 and will be updated as the picture moves.
Where that leaves the evening layer is where this page began: a root only extract at 300 mg, inside the studied range, with trial side effects at placebo level, contraindications named in plain text, and effects that hold across trial durations. That is the standard this Library demands of an ingredient, and ashwagandha meets it.
In the system
The efficacy case and dose reasoning live on the ashwagandha page; the stress physiology it acts on is in cortisol and the stress curve. Build your protocol →
Sources
Next in this thread
Ashwagandha, KSM-66The efficacy case this safety page completes: dose, form, and graded evidence.→How we handle evidence. This safety page was written to the standard an outside sceptic would apply: trial data first, case reports named, anecdotes neither dismissed nor promoted, regulatory motion date-stamped. Educational content, not medical advice.